LargeV Instrument’s IPO on STAR Board Halted Following Filing and Sponsorship Withdrawal
The initial public offering (IPO) of LargeV Instrument Corp., Ltd to the Shanghai Stock Exchange’s...
IPO
Jiangsu QYuns Therapeutics Eyes HK IPO to Raise Up to HKD 243 Million for Autoimmune Pipeline
Jiangsu QYuns Therapeutics Co., Ltd. (HKG: 2509), based in China, is poised to launch an...
TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline
Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on...
Meizhong Jiahe Medical Debuts on Hong Kong Stock Exchange Below IPO Price
China-based Meizhong Jiahe Medical Science & Technology Development Co., Ltd has completed its initial public...
Weigao Blood Purification Aims for USD 190 Million in Shanghai Stock Exchange IPO
Shandong Weigao Blood Purification Products Co., Ltd, a dominant player in China’s blood purification sector,...
HighTide Therapeutics Inc. Raises USD 25 Million in Hong Kong IPO
HighTide Therapeutics Inc., (HKG: 2511) a China-based biopharmaceutical company, has successfully completed an initial public...
WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange
WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman...
Jiangxi Rimag Group Eyes Hong Kong IPO to Expand Medical Imaging Services
Jiangxi Rimag Group Co., Ltd (HKG: 2522), a China-based medical imaging specialist, is planning an...
Lizhu Pharmaceutical Cancels ChiNext IPO, Opts for NEEQ Listing for Subsidiary Lizhu Reagent
On November 11, 2023, Lizhu Pharmaceutical (HKG: 1513) announced a strategic shift in its plans...
WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Jiangsu QYuns Therapeutics Plans IPO on Hong Kong Stock Exchange
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has announced its intention to pursue an...
Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million
Sino-US biotech Adlai Nortye Ltd (NASDAQ: ANL) successfully completed its initial public offering (IPO) on...
Sandoz Becomes Independent After Spin-Off from Novartis
Switzerland-based generic and biosimilar drug maker Sandoz (SWX: SDZ) officially became a fully independent company...
Wuhan YZY Biopharma Aims to Raise HKD 220 Million in Hong Kong IPO
Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs...
ImmuneOnco Biopharmaceuticals Begins Trading on HKEX with Successful IPO
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) marked its debut on the Hong Kong Stock...
CSRC Aims to Rebalance Primary and Secondary Markets with New Regulatory Measures
The China Securities Regulatory Commission (CSRC) has released a document with the aim of “rebalancing”...
ImmuneOnco Biopharmaceuticals Launches IPO to Raise HKD 319 Million on Hong Kong Stock Exchange
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) is poised to raise HKD 319 million (USD...
Hangzhou Minsheng Healthcare Aims to Raise RMB890 Million in Shenzhen GEM IPO
Hangzhou Minsheng Healthcare Co., Ltd. (SHE: 301507) is poised to raise RMB890 million through an...
WuXi Biologics Proposes Spin-Off and Listing of WuXi XDC on Hong Kong Stock Exchange
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...
Henlius Biotech Suspends IPO on STAR Market, Aims to Optimize Capital Strategy
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the suspension of its initial public...